IN SILICO DRUG DESIGNING APPROACHES FOR LATENT AUTOIMMUNE DIABETES IN ADULTS (LADA)

Abstract

Autoantibody positivity together with subsequent development of insulin deficiency led to the introduction of latent autoimmune diabetes in adults (LADA) or type 1.5 diabetes for this subgroup of diabetic patients who clinically resemble type 2 diabetes at diagnosis.  β- cell dysfunction in type 1.5 diabetes is caused mainly by Glutamic acid decarboxylase antibody (GADA). β- cell stress results in an induction of Heat shock protein 90(Hsp 90) expression, where Hsp 90 is a regulator of Class II antigen processing and presentation. In silico docking studies and drug likeliness analysis have shown that docking target protein  Hsp 90 α with the  ligands geldanamycin ,radicicol and chimeric ligand radanamycin had a protective role against autoimmune destruction. This study paves way for treating the autoimmune diabetes at the immunity level .